Bio-Techne Corp (TECH) concluded trading on Thursday at a closing price of $58.47, with 4.38 million shares of worth about $256.2 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -25.71% during that period and on July 24, 2025 the price saw a gain of about 5.71%. Currently the company’s common shares owned by public are about 156.76M shares, out of which, 154.99M shares are available for trading.
Stock saw a price change of 9.72% in past 5 days and over the past one month there was a price change of 16.94%. Year-to-date (YTD), TECH shares are showing a performance of -24.82% which decreased to -18.83% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $46.01 but also hit the highest price of $83.62 during that period. The average intraday trading volume for Bio-Techne Corp shares is 2.26 million. The stock is currently trading 10.51% above its 20-day simple moving average (SMA20), while that difference is up 15.13% for SMA50 and it goes to -6.85% lower than SMA200.
Bio-Techne Corp (NASDAQ: TECH) currently have 156.76M outstanding shares and institutions hold larger chunk of about 104.88% of that.
The stock has a current market capitalization of $9.17B and its 3Y-monthly beta is at 1.40. PE ratio of stock for trailing 12 months is 71.27, while it has posted earnings per share of $0.82 in the same period. Its PEG reads 7.23 and has Quick Ratio of 2.58 while making debt-to-equity ratio of 0.21. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for TECH, volatility over the week remained 4.98% while standing at 4.28% over the month.
Stock’s fiscal year EPS is expected to rise by 7.27% while it is estimated to increase by 7.85% in next year. EPS is likely to shrink at an annualized rate of 9.86% for next 5-years, compared to annual growth of 11.13% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Stephens on July 22, 2025 offering an Overweight rating for the stock and assigned a target price of $65 to it. Coverage by TD Cowen stated Bio-Techne Corp (TECH) stock as a Buy in their note to investors on July 09, 2025, suggesting a price target of $65 for the stock. Stock get an Outperform rating from Evercore ISI on March 18, 2025.
